Afinitor everolimus regulatory update

FDA's Oncologic Drugs Advisory Committee (ODAC) voted 10-0 that Novartis' Afinitor everolimus had a favorable benefit-risk profile to treat advanced pancreatic neuroendocrine tumors. The sNDA is under...